

# NeoPharm

[View the current NeoPharm Page on BioPortfolio.com](http://www.bioportfolio.com)

(<http://www.bioportfolio.com/biorporate/7437-NeoPharm.html>)

## Contact Details:

1850 Lakeside Drive

Waukegan

IL

60085

United States of America

Tel: 847-887-0800

Fax: 847-887-9281

Email: [investorrelations@neopharm.com](mailto:investorrelations@neopharm.com)

NeoPharm is a pharmaceutical Company engaged in the research and development of drugs for the diagnosis and treatment of various forms of cancer. Presently the Company has several drugs which are in varying stages of development: BUdR(Broxuridine), liposome encapsulated doxorubicin ("LED"), liposome encapsulated paclitaxel ("LEP"), liposome encapsulated antisense oligodeoxynucleotide ("LE-AON" and with LED and LEP the "Liposome Products"), IL-13 PE38QQR ("IL-13") and Mesothelin SS-(dsFv)-PE38 ("Mesothelin Mab"). IL-13 and Mesothelin Mab are both Ligand Target Cytotoxins that specifically target cancer cells and leave normal cells unaffected.

## Recent Publications by NeoPharm:



- [Synthesis of 1,3- and 1,2-diphosphatidylglycerol.](#)  
*A novel phosphonium salt methodology was utilized for the first time to...*18th July, 2007  
NeoPharm, Inc., 1850 Lakeside Drive, Waukegan, IL 60085, USA.- Lipids. 2007 Apr;42(3):291-6. Epub 2007 Feb 7. ([DOI Direct Link](#))
- [In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate.](#)  
*Our objectives were to study the biological activity of a novel...*28th October, 2006  
Research and Development, NeoPharm Inc., Waukegan, Illinois 60085, USA.- Anticancer Drugs. 2006 Jan;17(1):53-61.
- [A novel cationic cardiolipin analogue for gene delivery.](#)  
*The optically active R and S isomers of cationic cardiolipin analogues...*11th March, 2006  
NeoPharm, Inc, Waukegan, IL 60085, USA.- Pharmazie. 2006 Jan;61(1):10-4.
- [pH-dependent association of SN-38 with lipid bilayers of a novel liposomal formulation.](#)  
*The aim of this study was to determine the location of SN-38 molecules in...*1st March, 2006  
Research & Development, NeoPharm Inc., Waukegan, IL 60085, USA.- Int J Pharm. 2005 Aug

- 11;299(1-2):92-9. ([DOI Direct Link](#))
- [Synthesis of cationic cardiolipin analogues.](#)  
*An approach was developed to synthesize a new class of cationic...*17th February, 2006  
 Research and Development Facility, NeoPharm, Inc., 1850 Lakeside Drive,- Bioorg Chem. 2005  
 Oct;33(5):345-62. ([DOI Direct Link](#))
  - [Synthesis and biological evaluation of gemcitabine-lipid conjugate \(NEO6002\).](#)  
*A novel gemcitabine-lipid conjugate 5 was synthesized and tested for its...*12th October, 2005  
 NeoPharm Inc., Research and Development Facility, 1850 Lakeside Drive,- Bioorg Med Chem Lett.  
 2005 May 16;15(10):2571-4. ([DOI Direct Link](#))
  - [Tetragenococcus koreensis sp. nov., a novel rhamnolipid-producing bacterium.](#)  
*A Gram-positive, non-motile, non-spore-forming coccus (strain JS(T)) was...*1st October, 2005  
 NeoPharm Co., Ltd, BVC-307, KRIBB, 52 Oeun-dong, Yuseong-gu, Daejeon- Int J Syst Evol Microbiol.  
 2005 Jul;55(Pt 4):1409-13. ([DOI Direct Link](#))
  - [Quantification of raf antisense oligonucleotide \(rafAON\) in biological matrices by LC-MS/MS to support pharmacokinetics of a liposome-entrapped rafAON formulation.](#)  
*An LC-MS/MS method was developed to quantify an antisense oligonucleotide...*20th August, 2005  
 Pharmacokinetics, Safety and Efficacy Department, NeoPharm Inc., Waukegan,- Biomed Chromatogr.  
 2005 May;19(4):272-8. ([DOI Direct Link](#))
  - [A rapid isocratic high-performance liquid chromatography method for determination of cholesterol and 1,2-dioleoyl-sn-glycero-3-phosphocholine in liposome-based drug formulations.](#)  
*A high-performance liquid chromatography (HPLC) method for the...*19th August, 2005  
 Process Development and Manufacturing Department, Research and- J Chromatogr A. 2005 May  
 6;1073(1-2):347-53.
  - [Liquid chromatographic-tandem mass spectrometric assay for the simultaneous quantification of Camptosar and its metabolite SN-38 in mouse plasma and tissues.](#)  
*A simple, rapid and sensitive LC-MS/MS bioanalytical method has been...*19th August, 2005  
 Pharmacokinetics, Safety, and Efficacy Department, Research and- J Chromatogr A. 2005 May  
 6;1073(1-2):249-55.
  - [Separation of liposome-entrapped mitoxantrone from nonliposomal mitoxantrone in plasma: pharmacokinetics in mice.](#)  
*A method is described for quantification of the liposomal and nonliposomal...*9th August, 2005  
 NeoPharm, Inc., Research and Development, Waukegan, IL 60085, USA.- Methods Enzymol.  
 2005;391:176-85. ([DOI Direct Link](#))
  - [Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer.](#)  
*Raf-1, a protein serine-threonine kinase, plays a critical role in...*29th July, 2005  
 Pharmacokinetics, Safety and Efficacy Department, NeoPharm Inc., Research- Int J Oncol. 2005  
 Apr;26(4):1087-91.
  - [Preparation, characterization, and stability of liposome-based formulations of mitoxantrone.](#)  
*The preparation, characterization, and stability of lyophilized...*23rd July, 2005  
 NeoPharm, Inc, Waukegan, Illinois, USA.- Drug Dev Ind Pharm. 2005 Jan;31(2):223-9.
  - [A simple and sensitive LC/MS/MS assay for 7-ethyl-10-hydroxycamptothecin \(SN-38\) in mouse plasma and tissues: application to pharmacokinetic study of liposome entrapped SN-38 \(LE-SN38\).](#)  
*An LC/MS/MS method to quantify SN-38 in mouse plasma and tissue...*18th June, 2005  
 Pharmacokinetics, Safety and Efficacy Department, Research and- J Pharm Biomed Anal. 2005 Feb  
 7;37(1):135-42. ([DOI Direct Link](#))
  - [Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation.](#)  
*BACKGROUND: SN-38, 7-ethyl-10-hydroxycamptothecin, is a biologically...*17th May, 2005  
 NeoPharm, Inc, Research and Development, Waukegan, IL 60085, USA.- Anticancer Res. 2005  
 Jan-Feb;25(1A):331-41.



- [NeoPharm, Inc. Announces Second Quarter 2008 Financial Results](#)  
*Therapeutics Daily: Aug 21 2008 10:10PM Matching: neopharm*
- [NeoPharm, Inc. Announces Second Quarter 2008 Financial Results](#)  
*DiGiTAL50: Aug 16 2008 12:47AM Matching: neopharm*
- [Addressing the Cardiovascular Risk in Rheumatoid Arthritis](#)  
*Abstracts in Hematology and Oncology: Aug 4 2008 10:32PM Matching: neopharm*
- [Addressing the Cardiovascular Risk in Rheumatoid Arthritis](#)  
*Medscape: Jul 31 2008 4:30PM Matching: neopharm*
- [Horizon Therapeutics names new president and CEO](#)  
*Pharmaceutical Business Review: Jul 26 2008 5:46AM Matching: neopharm*
- [Horizon Therapeutics Names Timothy P. Walbert as President and CEO](#)  
*Pharma Live: Jul 24 2008 11:47PM Matching: neopharm*
- [Horizon Therapeutics Names Timothy P. Walbert as President and CEO](#)  
*Portland Business Journal: Jul 24 2008 1:47PM Matching: neopharm*
- [Horizon Therapeutics Names Timothy P. Walbert as President and CEO](#)  
*Columbus Business First: Jul 24 2008 1:47PM Matching: neopharm*
- [Horizon Therapeutics Names Timothy P. Walbert as President and CEO](#)  
*Cincinnati Business Journal: Jul 24 2008 1:16PM Matching: neopharm*
- [NeoPharm Receives NASDAQ Notice](#)  
*Pharma Live: Jun 27 2008 11:43AM Matching: neopharm*
- [NeoPharm Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market](#)  
*Pharma Live: Jun 12 2008 1:27PM Matching: neopharm*

**NeoPharm Patents:**



- 7390502- [SN-38 lipid complexes and their methods of use](#)
- 7314637- [Method of administering liposomal encapsulated taxane](#)
- 7262173- [Chemosensitizing with liposomes containing oligonucleotides](#)
- 7122553- [Liposomal formulation of irinotecan](#)
- 6461637- [Method of administering liposomal encapsulated taxane](#)
- 6146659- [Method of administering liposomal encapsulated taxane](#)

**BioCorporate Profiles - upgrade to a full profile**

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services.

BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's relate service indepth.

The annual cost is \$495.00 for established organizations and \$295.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

